We offer FREE SHIPPPING on all orders!
We offer FREE SHIPPPING on all orders!
| THIS PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for invitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly prohibited by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food, or cosmetic. |
Trenbolone Hexahydrobenzylcarbonate 100 is an injectable preparation containing 100 mg of trenbolone hexahydrobenzylcarbonate per milliliter. The compound is commonly abbreviated trenbolone hex and is historically associated with the pharmaceutical product Parabolan.
Trenbolone is a potent synthetic anabolic-androgenic steroid from the 19-nortestosterone family. The hexahydrobenzylcarbonate ester provides a relatively prolonged release compared with the short acetate ester.
The compound consists of trenbolone attached to a hexahydrobenzylcarbonate ester.
The ester primarily modifies the rate at which trenbolone is released following injection. After the ester is cleaved, the active steroid is trenbolone.
This means trenbolone acetate, enanthate, and hexahydrobenzylcarbonate ultimately expose tissues to the same parent steroid. Their major difference is their pharmacokinetic profile.
A concentration of:
Trenbolone Hexahydrobenzylcarbonate: 100 mg/mL
means that each milliliter contains 100 mg of the complete esterified compound.
Because the hexahydrobenzylcarbonate ester contributes substantial molecular weight, 100 mg of the compound does not represent 100 mg of free trenbolone.
Based on molecular weights, trenbolone hexahydrobenzylcarbonate is approximately 66% trenbolone by weight, so 100 mg contains roughly 66 mg of trenbolone after accounting for the ester.
This is a chemical comparison and not a dosing recommendation.
Trenbolone hexahydrobenzylcarbonate is unusual among trenbolone preparations because it has a history of legitimate human pharmaceutical use.
It was marketed historically under the name Parabolan, particularly in France. That pharmaceutical product was eventually discontinued and trenbolone is not currently an approved human therapeutic drug in the United States.
This historical medical use should not be interpreted to mean that modern underground products labeled "Parabolan" are equivalent to the former pharmaceutical preparation.
Once released from its ester, trenbolone binds strongly to androgen receptors.
Androgen receptors are present in skeletal muscle and numerous other tissues. Their activation influences gene transcription, protein metabolism, nitrogen balance, and other androgen-dependent processes.
Trenbolone's substantial anabolic activity explains much of its reputation in bodybuilding and physique-enhancement settings.
Potent anabolic activity, however, does not indicate a favorable safety profile.
Trenbolone can create an environment favorable to maintaining or increasing lean tissue through androgen-receptor-mediated effects involving protein synthesis and nitrogen retention.
It is frequently characterized as considerably more anabolic than testosterone. Precise numerical "anabolic ratings" often quoted online should be interpreted cautiously because they are largely derived from experimental models and do not function as reliable human potency or safety scales.
Human outcomes depend on exposure, individual biology, training, nutrition, concurrent drugs, and numerous other factors.
The primary distinction is the ester.
Trenbolone Acetate uses a small acetate ester and produces a relatively rapid release.
Trenbolone Hexahydrobenzylcarbonate uses a considerably larger ester and provides a more prolonged release.
The larger ester also means that an equal labeled milligram quantity contains proportionally less actual trenbolone.
Once the respective esters have been removed, however, both produce trenbolone.
Trenbolone enanthate and trenbolone hex are both longer-acting esterified forms of trenbolone.
Their ester structures differ, so their exact pharmacokinetic profiles are not identical. Nevertheless, both are designed to provide a considerably more prolonged release than trenbolone acetate.
Again, the ester changes delivery rather than changing the identity of the active steroid.
Trenbolone is not a testosterone ester.
Testosterone cypionate, enanthate, propionate, and suspension all ultimately deliver testosterone.
Trenbolone hexahydrobenzylcarbonate delivers trenbolone, a distinct synthetic androgen with different metabolism and pharmacological properties.
Both interact with androgen receptors, but their behavior in other hormonal pathways differs considerably.
Trenbolone itself is generally considered non-aromatizing.
Unlike testosterone, it is not directly converted into estradiol by aromatase.
This does not mean trenbolone creates a simple estrogen-free endocrine environment or eliminates hormone-related side effects. Trenbolone belongs to the 19-nor family and has activity involving progesterone receptors.
When multiple anabolic compounds are being used simultaneously, determining the cause of breast symptoms, libido changes, or sexual dysfunction can therefore become complicated.
Automatically treating such symptoms as "high estrogen" or "high prolactin" without appropriate evaluation can be misleading.
Trenbolone has substantial androgenic activity.
Potential androgen-related effects include:
Genetics play an important role in determining how strongly these effects appear.
Trenbolone can strongly suppress the hypothalamic-pituitary-gonadal axis.
External androgen exposure produces negative feedback that reduces LH and FSH signaling.
The testes can consequently reduce endogenous testosterone production substantially.
Possible consequences include reduced natural testosterone production, decreased testicular volume, sexual-function changes, impaired sperm production, and infertility.
The longer ester may also mean exposure persists for a meaningful period after the final administration.
Suppression of LH and FSH can substantially interfere with spermatogenesis.
Possible consequences include reduced sperm counts and, in some individuals, azoospermia.
Recovery after discontinuation varies and cannot reliably be predicted from a particular ester or timeline.
Anyone concerned about fertility should discuss testing and fertility preservation with an appropriate medical specialist.
Cardiovascular health is one of the major concerns surrounding nonmedical anabolic-androgenic steroid exposure.
Potential concerns include:
Risk is influenced by total exposure, duration, concurrent substances, age, genetics, blood pressure, cholesterol, smoking, and underlying cardiovascular health.
The absence of aromatization does not mean the compound is cardiovascularly benign.
Androgens can affect erythropoiesis and therefore influence hemoglobin and hematocrit.
Significant hematocrit elevations can increase blood viscosity and warrant medical evaluation.
CBC monitoring can therefore provide important information for someone exposed to anabolic-androgenic steroids.
People using trenbolone frequently report:
These reports are common in bodybuilding communities, but controlled human research specifically quantifying these effects is limited.
Persistent night sweats or significant sleep disruption can also have unrelated medical causes and should not automatically be attributed to trenbolone.
Reported effects during anabolic-steroid exposure can include changes in mood, irritability, anxiety, aggression, and sleep.
Responses vary considerably between individuals.
Severe insomnia, depression, anxiety, aggression, or significant behavioral changes warrant medical attention rather than simply being regarded as expected effects of a compound.
Trenbolone's effects on sexual function are not predictable from androgenic potency alone.
Strong androgen-receptor activation can occur simultaneously with suppression of endogenous testosterone and disruption of the normal reproductive endocrine system.
Users consequently report a wide range of effects, including both increased and decreased libido and erectile difficulties.
Trenbolone has a reputation in bodybuilding communities for causing kidney problems, but controlled human evidence specifically isolating trenbolone's direct renal toxicity is limited.
Renal laboratory interpretation can also be complicated in muscular individuals because creatinine is affected by muscle mass, intense exercise, diet, hydration, and creatine supplementation.
Nevertheless, abnormal kidney function, persistent protein in the urine, uncontrolled blood pressure, or other renal abnormalities require medical evaluation.
Trenbolone hexahydrobenzylcarbonate is injectable and is not a conventional 17-alpha-alkylated oral anabolic steroid.
It therefore differs from oral anabolic steroids specifically modified to withstand extensive first-pass hepatic metabolism.
That does not mean abnormal liver tests should be ignored. Persistent abnormalities require appropriate clinical investigation.
Any injectable preparation carries risks such as:
Unregulated products add additional uncertainty regarding sterility, contamination, actual concentration, and whether the stated drug is actually present.
Progressive redness, warmth, severe pain, swelling, drainage, or fever following an injection warrants medical evaluation.
Potential or reported concerns associated with trenbolone/AAS exposure include acne, oily skin, androgenic hair loss, suppression of endogenous testosterone, impaired fertility, adverse cholesterol changes, increased blood pressure, cardiovascular strain, sleep disturbance, night sweats, mood changes, sexual dysfunction, and injection-related complications.
Modern trenbolone hex products marketed for bodybuilding do not have an established approved human dosing framework.
Compound: Trenbolone Hexahydrobenzylcarbonate
Common Abbreviation: Trenbolone Hex / Tren Hex
Historical Pharmaceutical Name: Parabolan
Common Concentration: 100 mg/mL
Drug Class: Anabolic-androgenic steroid
Active Steroid: Trenbolone
Ester: Hexahydrobenzylcarbonate
Release Profile: Long acting relative to trenbolone acetate
Approximate Trenbolone Content: About 66 mg trenbolone per 100 mg esterified compound
Anabolic Activity: High
Androgenic Activity: High
Direct Aromatization to Estradiol: No
Progestogenic Activity: Present
Suppresses Natural Testosterone: Yes
Can Impair Fertility: Yes
Historical Human Pharmaceutical Use: Yes
Current U.S. Human Approval: No
Trenbolone Hexahydrobenzylcarbonate 100 is a long-acting esterified form of trenbolone historically associated with Parabolan. Its large ester provides a more prolonged release profile than trenbolone acetate while ultimately delivering the same active steroid: trenbolone.
The compound is notable for strong anabolic and androgenic activity, lack of direct aromatization into estradiol, and substantial suppression of normal reproductive hormone signaling. The same pharmacology responsible for its anabolic effects can also affect cardiovascular risk factors, fertility, natural testosterone production, skin and hair, sleep, mood, and sexual function.
Although trenbolone hex has a history of pharmaceutical human use, that history does not establish modern bodybuilding use as safe, and currently marketed unregulated preparations should not be assumed to have the purity, sterility, or consistency of the former pharmaceutical product.
We do not accept returns or issue refunds for any reason, beside manufacturing defects.
Feel free to contact us if you have any questions or concerns about our Return Policy.
